About Us

03-13

Guo Zhijun

Mr. Zhijun Guo is the Chief Technology Officer at Immorna and Co-founder of the Immorna family of companies. He has more than 30 years of scientific and leadership experience in the infectious disease vaccine industry. Prior to co-founding Immorna with Dr. Zihao Wang, Mr. Guo was Associate General Manager at King-cell Biotechnology (Shanghai) where he established the full quality system to support the drug lifecycle management as a whole, and led the GMP compliance taskforce. Prior to King-cell, Mr. Guo worked for more than 15 years at Tianyuan Biopharmaceutical Co. Ltd. (part of Novartis Vaccines and Diagnostics, then GSK Vaccines) with increasing technical and leadership roles. He was Head of the Manufacturing Science & Technology function before he left GSK Vaccines. Mr. Guo is a well-recognized expert in CMC development, tech transfer, process validation, and GMP manufacturing. He also has extensive experience in regulatory submissions for all phases of vaccine clinical trials and commercial product registration. He led the successful registration of Novartis and GSK rabies, human papillomavirus (HPV) and quadrivalent influenza vaccines. Mr. Guo holds an MBA degree from the University of Montpellier in France.

03-13

Cai Ji

Mr. Cai Ji, Director of Manufacturing Science and Technology Department, is responsible for the GMP production of the company's clinical filing projects and clinical study drugs. He has nearly 10 years of experience in downstream purification process development, GMP production and project management. As the project leader of Afamelanotide, he was responsible for the whole process from process development to NDA filing. Worked as a key participant in the full process from process development to NDA filing in the EU for the drug API Bulevirtide, a drug pipeline that was later acquired by Gilead. During his tenure, as a project leader, he was responsible for the process development and manufacturing of 10~20 IND PhaseI~PhaseII drugs per year. As a GMP Production Director, he has managed nearly 100 employees under the production department and has many years of experience in people management and project management. Since joining Imona, he has completed the GMP manufacturing of four FDA IND projects and was responsible for writing some of the filings. She has also completed one IND filing and two IIT clinical drug manufacturing projects in China.

01-29

Innovative technology-driven, to create a professional mRNA CDMO

Recently, an innovative technology-driven company announced that it will invest significant resources to build professional mRNA CDMO services. As a subversive treatment, mRNA has been widely used in vaccine and gene therapy, and its potential is immeasurable. The company is determined to provide customers with high-quality and reliable mRNA CDMO services through innovative technology leadership to help the industry grow.

04-10

Business and services related to mRNA CDMO

In recent years, the related business of mRNA CDM (grassland thief swine encephalitis vaccine) has become a hot topic in the biopharmaceutical industry. As an innovative vaccine technology, mRNA CDM has shown great potential in the field of disease prevention and treatment.

04-10

New Technologies Brought by mRNA CDMO

In recent years, the emergence of mRNA CDM(messenger RNA cell delivery technology) has triggered a new round of technological revolution. As an mRNA-based cell delivery technology, the application prospect of mRNA CDM is exciting.

01-29

Progress of mRNA CDMO Vaccine

Significant breakthrough in mRNA CDMO vaccine progress! Recently, a leading mRNA CDMO (Contract Development and Manufacturing Organization) company announced that they are accelerating the development of a new vaccine to combat the current global epidemic. The news has raised hopes for controlling the epidemic.